Janjigian et al. conducted CheckMate-649, a randomized, multicenter, phase III trial that aimed to assess the efficacy of combining nivolumab with chemotherapy vs. chemotherapy in patients with advanced, previously untreated, Human Epidermal growth factor Receptor-type 2 (HER-2)-negative G/GEJ cancer or esophageal adenocarcinoma (Table 2). The gene discussed is ERBB2; the disease is esophageal adenocarcinoma.